GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology.

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The purpose of this manuscript is to review the available antagonists of platelet glycoprotein (GP) IIb/IIIa. The critical role of platelet aggregation in the pathogenesis of acute coronary syndromes of unstable angina and non-Q-wave myocardial infarction, as well as in mediating abrupt vessel closure and periprocedural infarction after percutaneous coronary interventions, has been recognised recently. Platelet aggregation is mediated through expression of activated GP IIb/IIIa and its subsequent binding to circulating fibrinogen. Inhibition of this interaction with one of 3 commercially available agents has been demonstrated to reduce ischaemic complications of coronary intervention and to reduce the rates of death and myocardial infarction in patients with acute coronary syndromes. Differential pharmacological characteristics of the drugs abciximab, tirofiban and eptifibatide are described and the trials which have defined their role in the management of ischaemic heart disease are reviewed.

Original languageEnglish (US)
Pages (from-to)361-370
Number of pages10
JournalDrugs in R&D
Issue number5
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology.'. Together they form a unique fingerprint.

Cite this